Abstract New hydroxymethyl-pyridine esters of the formula (I) <IMAGE> (I) wherein R represents a 9-xanthenyl group or a phenyl group substituted by a halogen atom or a trifluoromethyl group or by an alkyl or alkoxy group, either having 1 to 4 carbon atoms, and pharmaceutically acceptable acid addition salts and quaternary salts thereof are prepared by acylating the corresponding hydroxymethyl pyridines with a carboxylic acid of the formula R-COOH, or with a reactive derivative thereof, and, if desired, converting the obtained product of the formula I into a pharmaceutically acceptable acid addition salt or quaternary salt thereof. The new compounds exert beneficial effects on functional disorders of the heart.
An antiarrhythmic pharmaceutically effective compound selected from the group which consists of: 3-[(3-trifluoromethylbenzoyl)-oxymethyl]-pyridine methyliodide; 3-[(4-fluorobenzoyl)-oxymethyl]-pyridine methyliodide; and 2-[(2-chlorobenzoyl)-oxymethyl]-pyridine methyliodide.
Claim 2
Dependent Claim
19 words
An antiarrhythmic pharmaceutically effective compound selected from the group which consists of: 3-[(3-trifluoromethylbenzoyl)-oxymethyl]-pyridine methyliodide; 3-[(4-fluorobenzoyl)-oxymethyl]-pyridine methyliodide; and 2-[(2-chlorobenzoyl)-oxymethyl]-pyridine methyliodide.